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Introduction
It is now largely accepted that chronic lymphocytic
leukemia (CLL) fits best the model of a compartmentalized
disease, with the proliferative component localized almost
exclusively in lymphoid organs.1,2 Here, environmental inter-
actions appear to fine tune the competence of leukemic cells
to survive, grow and eventually become resistant to therapy.
Distinct receptor-ligand pairs, as well as soluble molecules
mediating crosstalk between CLL cells and stromal-derived
elements, are attracting increasing attention as potential ther-
apeutic targets.3,4 In addition, several lines of evidence indicate
that CLL development and progression is accompanied by a
progressive impairment of the host immune defenses. CLL is
frequently associated with clinically manifest immune defects
of the T-cell compartment, with abnormalities in the pheno-
type of CD4+ and CD8+ T-cell subsets. A common finding is
the accumulation of terminally differentiated effector memo-
ry T cells, with a relative decrease of naïve precursors.5,6
Furthermore, decreased T-cell responses to mitogenic and T-
cell receptor-mediated stimulations have been described in
patients with CLL.7,8 Histological studies of CLL lymph node
(LN) samples have shown that within the proliferation cen-
ters (PC) (the counterpart of germinal centers9), leukemic cells
are in close contact with a population of CD4+/CD25+/Foxp3-
T lymphocytes.10 In addition, the success of CLL engraftment
and growth in an immunodeficient mouse was found to be
selectively dependent on activated autologous T lympho-
cytes, implying that this population is essential for in vivo neo-
plastic cell survival and proliferation.11
The mechanisms responsible for T-cell dysfunction in CLL
remain unclear, even if several independent observations
point to “frustrated” chronic antigen stimulation as a feature
of the disease. In line with this hypothesis, T lymphocytes
from CLL patients express markers of chronic activation, with
an inversion of the normal CD4:CD8 ratio, highly reminis-
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Chronic lymphocytic leukemia is marked by profound defects in T-cell function. Programmed death-1 is a receptor
involved in tumor-mediated immunosuppression through binding of the PD-L1 ligand. Multiparametric flow
cytometry and immunohistochemistry were used to study PD-1/PD-L1 expression. Functional assays were used
to determine the involvement of the PD-1/PD-L1 axis in T-cell responses. PD-1 expression by CD4+ and CD8+ T
lymphocytes was significantly higher in 117 chronic lymphocytic leukemia patients than in 33 donors of a com-
parable age. CD4+ and CD8+ T lymphocytes from chronic lymphocytic leukemia patients displayed increased
numbers of effector memory and terminally differentiated cells, respectively, when compared to controls. The
number of effector memory CD4+ and terminally differentiated CD8+ lymphocytes positively associated with a
more advanced stage of disease, treatment requirements and unfavorable genomic aberrations. Furthermore,
leukemic lymphocytes expressed higher levels of PD-L1 than circulating B lymphocytes from normal donors. PD-
1 and PD-L1 surface expression spiked in proliferating T and B lymphocytes, suggesting that this interaction works
efficiently in activated environments. Within chronic lymphocytic leukemia proliferation centers in the lymph
node, CD4+/PD-1+ T lymphocytes were found to be in close contact with PD-L1+ chronic lymphocytic leukemia
cells. Lastly, functional experiments using recombinant soluble PD-L1 and blocking antibodies indicated that this
axis contributes to the inhibition of IFN-γ production by CD8+ T cells. These observations suggest that pharmaco-
logical manipulation of the PD-1/PD-L1 axis may contribute to restoring T-cell functions in the chronic lympho-
cytic leukemia microenvironment.
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ABSTRACT
cent of the clinical picture described for patients with
chronic infections.6,12 CD4+ and CD8+ T lymphocytes from
CLL patients show distinct gene profiles,13 with alterations
in multiple genetic pathways, including the actin
cytoskeleton.14 Functional studies confirmed that these T
cells have defects in F-actin polymerization and immune
synapse formation with antigen presenting cells, both
essential steps in the generation of competent cytotoxic T
cells. The transmission of an immunosuppressive signal
has been attributed to the interaction of inhibitory recep-
tors expressed by CLL T lymphocytes (including CD200R,
CD272 and CD279) with ligands expressed by leukemic
cells (including CD200, CD270, CD274 and CD276).15
We investigated expression and functional significance
of programmed death-1 (PD-1, CD279), a cell surface mol-
ecule involved in tumor-mediated suppression of activated
immune cells through binding of the PD-L1 ligand, in a
cohort of 117 CLL patients and compared them to age-
matched controls. Results provide evidence of an active
crosstalk between PD-1 expressed by CD4+ and CD8+ sub-
sets and PD-L1 expressed by the leukemic counterpart,
operative within the PC in the CLL LN. Signaling through
PD-1 contributes to blocking IFN-γ secretion, with the
final effect of a pronounced Th2 skewing of T-cell
responses. These findings identify the PD-1/PD-L1 axis as
an important component that contributes to dysfunctional
interactions between leukemic CLL cells and host T lym-
phocytes.
Design and Methods
Patients’ samples
Peripheral blood samples were obtained from 117 patients
(51% males) with a confirmed diagnosis of CLL (mean age 63
years). Thirty-three donors (54% males) with no evidence of
leukemia and comparable age (mean age 65 years) were kindly
provided by the local blood bank (Online Supplementary Table S1).
Blood was drawn after informed consent, in accordance with
Institutional Guidelines and the Declaration of Helsinki. The study
was approved by the Human Genetics Foundation (HuGeF) ethi-
cal committee. Peripheral blood mononuclear cell (PBMC) prepa-
ration and B-cell purification were as described in the Online
Supplementary Appendix. Sample analyses included CD38 and
ZAP-70 staining (cut-off positivity values of 20%), IgVH mutation-
al status (unmutated if ≥98% homology to the germ-line gene) and
fluorescence in situ hybridization (FISH) for chromosomes 11, 12,
13 and 17 (Online Supplementary Table S1). 
FACS analyses
Antibodies used for flow cytometry were anti-CD4-PE-Cy5, -
CD45RO-PE, -PD-L1-PE-Cy7, -IL4-FITC, -IFN-γ-PE (all from
eBioscience, Milan, Italy), -CD8-FITC, -PD-1-PE-Cy7, -CD45RA-
APC-Cy7 (Biolegend, Milan, Italy) and anti-CCR7-FITC (R&D
System, Milan, Italy). Data were acquired using a FACSCanto II
cytofluorimeter (BD Biosciences, Milan, Italy) and processed with
DIVA version 6.1.3 (BD Biosciences) and FlowJo version 9.01 soft-
wares (TreeStar, Ashland, OR, USA). At least 10,000 events were
analyzed for each sample.
Immunohistochemistry and immunofluorescence
microscopy 
Formalin-fixed, paraffin-embedded sections of LNs infiltrated
by CLL cells (n=20) were obtained from the Department of
Pathology of the University of Turin, Italy, and from the
Department of Hematology of the Dubrava University Hospital,
Zagreb, Croatia. The main clinical characteristics of this patient
cohort are reported in Online Supplementary Table S2. A detailed
description of preparation of slides can be found in the Online
Supplementary Appendix.
Proliferation assays
Full details can be found in the Online Supplementary Appendix.
Intracytoplasmic staining for cytokine production
PBMC were activated for four days with anti-CD3 and -CD28
mAbs, as detailed above, with or without recombinant soluble
PD-L1 (sPD-L1, 10 mg/mL, R&D Systems). Brefeldin A
(eBioscience) was added during the final four hours of culture.
Cytokines were measured by intracytoplasmatic staining with
anti-IL4-FITC and anti-IFN-γ-PE Abs after gating on CD4+ or CD8+
subsets, respectively. 
ELISpot assay
The frequency of IFN-γ-secreting T lymphocytes in cultures was
assessed in an ELISpot assay, as previously described.16 Full details
are to be found in the Online Supplementary Appendix.
Statistical analyses
Statistical analyses were carried out with GraphPad version 5
(GraphPad Software Inc, La Jolla, CA, USA) and the data are pre-
sented as box plots where the box represents the 25th (bottom) and
75th (top) percentiles; the band inside the box is the median. The
whiskers represent the minimum and maximum of all data. In the
text, data are presented as median ± standard error. 
Continuous variables were compared by Mann-Whitney test.
Wilcoxon’s matched-pairs signed rank test was used for paired
continuous variables. Data were analyzed with Prism software
version 5.0 (GraphPad Software). 
Results
CD4+ and CD8+ T lymphocytes from CLL patients 
show increased PD-1 expression as compared 
to controls with a comparable age
PD-1 surface expression was tested by flow cytometry
in T lymphocytes from CLL patients (n=117) and com-
pared to controls (n=33). The patients were either untreat-
ed or had received the last course of chemotherapy more
than three months previously. Three patients (8%) had
received anti-CD52-containing regimen (Online
Supplementary Table S1). By applying a sequential gating
strategy, based on morphological parameters and multi-
color flow cytometry (Online Supplementary Figure S1), PD-
1 was significantly increased in the CD4+ T-cell subset
from CLL patients, as compared to controls (Figure 1A).
Similar results were obtained when the CD8+ subset was
analyzed (Figure 1B). CLL patients displayed high variabil-
ity in both T-cell subsets, while PD-1 was homogeneously
expressed in T lymphocytes from all control samples test-
ed. Moreover, a fraction of CLL lymphocytes, identified
on the basis of CD19/CD5 surface expression, was PD-1+
(Figure 1C), confirming previous observations.17 On the
contrary, circulating B lymphocytes from controls were
mostly PD-1– (Figure 1C). 
The PD-L1 ligand was found to be restricted to B lym-
phocytes in CLL and control samples; however, CLL B
lymphocytes expressed significantly more PD-L1 when
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compared to B lymphocytes cells from controls (Figure
1D).
T lymphocytes from CLL patients show a marked
increase in terminally differentiated populations
PD-1 in human circulating CD4+ T cells marks chronical-
ly activated effector memory cells.18-20 On the contrary, PD-
1 is classically considered a marker of cell exhaustion in
the CD8 subset.21 Thus, the finding of an increased expres-
sion of PD-1 in T lymphocytes from CLL patients suggests
a relative enrichment in terminally differentiated cells as
compared to controls with a similar age. 
This hypothesis was tested by analyzing T-cell subpop-
ulations in the same cohorts as above. To do so, CD4+ and
CD8+ subset cells were stained with CD45RA and CCR7
in order to quantify the relative number of naïve, central
memory, effector memory and terminally differentiated
cells22 (Figure 2A). The latter population is virtually absent
in the CD4+ subset under physiological conditions, but
becomes apparent during chronic activation.23,24
Representative profiles from a CLL patient and a control
are reported in Figure 2A. Cumulative data indicated
marked differences in the composition of both CD4+ and
CD8+ T-cell subsets (Figure 2B). The most significant dif-
ferences in the CD4+ compartment concerned the decrease
of naïve cells and the relative increase of terminally differ-
entiated populations. Similar results were found in the
CD8+ compartment, with a decrease of central memory
cells and a concomitant increase in terminally differentiat-
ed cells. When determining PD-1 expression in the differ-
ent subsets we unexpectedly found that the molecule was
expressed by each subpopulation, including naïve cells.
However, it was clear that T lymphocytes from the 8
examined CLL patients displayed significantly higher lev-
els of PD-1 in naïve, central and effector memory subsets
when compared to the normal counterpart (n=5).
Terminally differentiated cells did not reach statistical sig-
nificance (Online Supplementary Figure S2). Increased PD-1
expression was also noted in naïve and central memory
CD8+ CLL T lymphocytes. No differences were observed
when comparing effector memory or terminally differen-
tiated cells  (Online Supplementary Figure S2). 
The increase in effector memory CD4+ and terminally
differentiated CD8+ T lymphocytes parallels disease
aggressiveness 
The heterogeneity in T-cell subset composition might
indicate that the degree of T-cell exhaustion varies accord-
ing to the stage and aggressiveness of the leukemia. For
this reason, the patient cohort was divided on the basis of
clinical and molecular markers of disease burden and
aggressiveness. Patients with a more advanced stage of
disease, as well as patients who required treatment, were
characterized by higher levels of circulating CD4+ effector
memory cells (Figure 2C). The same results were obtained
when considering terminally differentiated CD8+ cells
(Figure 2D).
In line with these results, the percentage of effector
memory CD4+ and terminally differentiated CD8+ lym-
phocytes was significantly lower in patients characterized
by favorable molecular markers, such as the presence of
mutations in the IgHV genes (Figure 2C) and the absence
of deleterious chromosomal deletions than in the counter-
part (Figure 2D).
PD-1 and PD-L1 are significantly up-modulated 
in proliferating T lymphocytes and CLL cells
We then asked whether PD-1/PD-L1 expression could
be modulated during cell activation. T lymphocytes from
CLL patients were activated using mitogenic anti-
CD3/CD28 mAbs and stained using CFSE. Proliferating
CD4+ and the CD8+ subsets were identified after applying
a morphological (FCS vs. SSC) gate, followed by staining
with anti-CD4 or -CD8 (Figure 3A). PD-1 expression
PD-1/PD-L1 axis in CLL
haematologica | 2013; 98(6) 955
Figure 1. Comparative analysis of the surface expression of PD-1 and its ligand PD-L1 in distinct lymphocyte subsets from CLL patients and
from age- and sex-matched donors. Representative dot plots showing surface expression of PD-1 in CD4+ (A), CD8+ (B) and CD19+ lympho-
cytes (C) from CLL patients (left side) or age- and sex-matched donors (right side). The expression of the PD-L1 ligand in the CD19+ subset
is shown in (D). Cumulative data from 117 CLL patients (gray bars) and 33 controls (open bars) are reported in the box plots on the right. 
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increased significantly in proliferating cells. The increase
was predominant in the CFSE+ proliferating compartment,
with intensity varying in function of the number of prolif-
eration cycles (Figure 3B). PD-1 increase following activa-
tion could also be observed in T cells from controls, as pre-
viously described25 (Figure 3B). However, the levels of PD-
1 expression in activated CD4+ and CD8+ T lymphocytes
from CLL patients were significantly higher than in con-
trols (Figure 3B).
Expression of the PD-L1 ligand increased sharply when
purified CLL cells were induced to proliferate by culturing
with immunostimulatory CpG nucleotides and IL-2.26
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Figure 2. Comparative analysis of T-
lymphocyte subpopulations in CLL
patients and in age- and sex-matched
donors. (A) Representative dot plots
showing flow cytometric analysis of
PBMC from CLL patients (left) or con-
trols (right) after staining for CD4,
CD8, CD45RA and CCR7. A first gate
was applied to identify CD4+ (blue) or
CD8+ (purple) subsets. The combina-
tion of CD45RA and CCR7 resulted in
the identification of naïve
(CD45RA+/CCR7+), central memory
(CD45RA-/CCR7+), effector memory
(CD45RA-/CCR7-) and terminally dif-
ferentiated (CD45RA+/CCR7-) subpop-
ulation. (B) Cumulative data showing
the distribution of CD4+ (left graph) or
CD8+ (right graph) lymphocyte subpop-
ulations in 109 CLL patients (gray box
plots) and 30 age-and sex-matched
controls (open bars). (C) and (D) Box
plots showing cumulative distribution
of CD4+/CD45RA-/CCR7- effector
memory CD4+ cells and of
CD8+/CD45RA+/CCR7- terminally dif-
ferentiated CD8+ cells, respectively, in
patient subsets divided according to
clinical markers of disease burden
(Binet stage or treatment require-
ment) or to molecular markers of dis-
ease aggressiveness (presence or
absence of mutations in the IgHV
genes and of deletions in chromo-
somes 11q and 17p).
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Proliferating CLL cells acquired PD-L1 surface expression,
with the majority of the clone becoming strongly positive
(Figure 3C). PD-L1 upregulation in B lymphocytes from
controls activated in the presence of the same signals was
only marginal and markedly lower than that observed in
proliferating CLL cells (Figure 3C). These results suggest
that the PD-1/PD-L1 axis is maximally active in an activat-
ed environment. 
PD-1+ T lymphocytes are in close contact 
with PD-L1 CLL cells in the PC
The proliferative CLL compartment is predominantly
hosted within the LN. For this reason, PD-1 and PD-L1
expression patterns were tested by immunohistochem-
istry and confocal microscopy in LN specimens obtained
from 20 patients with a confirmed diagnosis of CLL. All
samples displayed an almost complete effacement of the
PD-1/PD-L1 axis in CLL
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Figure 3. Expression
of the PD-1/PD-L1
pair in proliferating T
lymphocytes and CLL
cells. CFSE-labeled
PBMC preparations
from CLL patients or
age- and sex-matched
controls were treated
with mitogenic anti-
CD3 and anti-CD28
antibodies to trigger T-
cell proliferation or
with a combination of
CpG oligonucleotides
and recombinant
human IL-2 to induce
B-cell proliferation.
Morphological gating
based on FCS and
SSC parameters and
subsequent staining
with specific antibod-
ies allowed to identify
CD4+ (blue), CD8+ (pur-
ple) and CD19+ (red)
subsets (A).
Representative dot
plots show PD-1 and
PD-L1 expression in
proliferating CD4+,
CD8+ (B) and CD19+
(C) subpopulations.
Cumulative data from
CLL patients (gray
bars) and age- and
sex-matched controls
(open bars) are shown
in the box plots on the
right. 
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normal LN architecture by CLL cells, along with evidence
of morphologically distinct PC, with areas rich in prolym-
phocytes and para-immunoblasts. PD-1+ cells appeared
more concentrated in the paler areas classically associated
with the PC (Figure 4A), as also confirmed after Ki-67
staining (data not shown). Quantification of staining inten-
sity showed that PD-1 was expressed at significantly high-
er levels in the PC as compared to the other areas of the
specimen (Figure 4B). High magnification images indicat-
ed that PD-1 staining was limited to surface membranes
and associated with a distinct cell subset, overlapping
almost completely with the T-cell infiltrate, as identified
by CD2 staining in immunofluorescence experiments
(Figure 4C). Co-staining with an anti-CD4 mAb indicated
that the majority of these T lymphocytes are CD4+ (Online
Supplementary Figure S3). Reactive LN samples with clearly
identifiable and conserved follicles were characterized by
a subset of predominantly small lymphocytes in the ger-
minal centers showing intense staining for PD-1, in line
with previous data.27,28 PD-1 staining was also apparent in
the interfollicular areas, predominantly containing T lym-
phocytes (Figure 4D). Also in the case of reactive LN,
immunofluorescence confirmed that PD-1+ cells over-
lapped almost completely with the CD2+ subset (Figure
4E) and were mostly CD4+ (Online Supplementary Figure
S3).
PD-L1 expression in LN samples from CLL patients was
quite heterogeneous, with some samples (9 of 20) show-
ing a diffuse pattern, while others (10 of 20) displayed a
patchier reactivity and one sample was completely nega-
tive. (Figure 5A). In any case, the strongest intensity was
associated to the PC, as shown after quantification of PD-
L1 staining (Figure 5B). The PD-L1 staining pattern did not
show any clear-cut association with clinical parameters,
including disease stage or treatment, with the limits of the
cohort examined (Online Supplementary Table S2).
Immunofluorescence confirmed that PD-L1+ elements
were consistently CD23+ (Figure 5C), with the exception
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Figure 4. Immunohistochemistry and
immunofluorescence analysis of PD-
1 expression on CLL and reactive LN.
(A) Anti-PD-1 immunostaining of a
representative LN tissue section
using a goat HRP-polymer detection
system and 3,3’-diaminobenzidine
(brown signal). Low magnification
shows PD-1 expression around the
paler areas corresponding to the pro-
liferation centers. Original magnifica-
tion 4x and 40x. (B) Quantification of
staining intensity was performed by
comparing the percentage of PD-1+
areas in 20x magnification images of
PC (shaded box plot) to other (open
box plot) parts of the same slide.
Analyses were performed using 4 dif-
ferent samples and at least 6 inde-
pendent images of PC vs. 6 of other
areas per sample.  (C) Double stain-
ing of a representative CLL LN tissue
section with anti-PD-1 (green) and
anti-CD2 (red). Merged panel shows
that the majority of PD-1+ cells are
CD2+ T lymphocytes. Original magni-
fication 63x. Scale bar represents 50
mm. (D) Anti-PD-1 immunostaining of
a representative reactive LN tissue
section. (E) Double staining of a rep-
resentative germinal center from a
reactive LN tissue section with anti-
PD-1 (green) and anti-CD2 (red).
Original magnification 63x. Scale bar
represents 50 mm.
Immunohistochemical images were
analyzed using a Leica DMI 3000 B
optical microscope (Leica
Microsystesms), equipped with a DCF
310 FX digital camera and LAS V3.8
software. Immunofluorescence
analysis was performed using a TCS
SP5 laser scanning confocal micro-
scope (Leica Microsystems) with an
oil immersion 63x/1.4 objective lens-
es, images were acquired with the
LAS AF software and processed with
Adobe Photoshop (Adobe Systems,
San Jose, CA, USA).
A
C
D
E
B
50
40
30
20
10
0
PC Other
P<0.0001
%
 o
f P
D-
1+
ar
ea
CL
L 
ly
m
ph
 n
od
e
Re
ac
tiv
e 
ly
m
ph
 n
od
e
PD-1
PD-1
Green: PD-1; Red: CD2
Green: PD-1; Red: CD2
of small vessels, which were confirmed as weakly PD-L1+
28 (Figure 5C). 
Simultaneous staining for PD-1, PD-L1 and CD3 in LN
samples from CLL patients indicate that PD-L1+ leukemic
lymphocytes are preferentially located in close proximity
to PD-1+ T lymphocytes (Figure 5D). This conclusion was
confirmed by quantifying relative fluorescence intensity of
PD-L1 in CD3high vs. CD3low areas (Figure 5E).
The expression of PD-L1 in reactive LN samples was
confined to the endothelial cells lining the vessels (Figure
5F), as also confirmed by immunofluorescence (Online
Supplementary Figure S4).
In conclusion, data from tissue sections indicate that the
PC of CLL LN hosts CD4+ T lymphocytes expressing PD-
1 and CLL cells expressing the PD-L1 ligand, suggesting a
direct contribution of the PD-1/PD-L1 axis in the intense
crosstalk occurring between the two cell populations in
this environment. 
PD-1/PD-L1 crosstalk contributes to suppressing 
IFN-γ production in CD8+ T lymphocytes 
Multiple reports indicate that T lymphocytes from CLL
patients are partially dysfunctional, with a Th2 skew-
ing.29,30 Our results obtained with intracytoplasmic staining
confirmed that CD4+ T lymphocytes from CLL patients
(n=12) produce significantly more IL-4 than those
obtained from appropriate controls when activated in the
presence of mitogenic anti-CD3/CD28 mAbs, (Figure 6A
and B). On the contrary, CD8+ T lymphocytes from CLL
patients produced significantly lower amounts of IFN-γ as
compared to controls (Figure 6A and B). No significant dif-
ferences between CLL and controls were observed in
terms of proliferative responses (data not shown).
We then asked whether the PD-1/PD-L1 axis can mod-
ulate cytokine secretion by different T-cell subsets, con-
tributing to the Th2 skewing that characterizes T-cell
responses in CLL. To do so, T lymphocytes were treated
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Figure 5. PD-L1 expressing CLL cells are
in close contact with PD-1+ T lympho-
cytes. (A) Anti-PD-L1 immunostaining of
two representative CLL LN tissue sec-
tions, displaying a diffuse or a patchy
reactivity. Original magnification 20x. (B)
Quantification of PD-L1+ areas showed
that the highest expression is associated
to the PC. Analyses were performed
using 4 different samples and at least 6
independent images of PC vs. 6 of other
areas per sample. (C) Double staining of
a representative CLL LN section with
anti-CD23 (green) and anti-PD-L1 (red)
confirms that PD-L1 expressing cells are
CD23+ CLL B lymphocytes.  The white
arrows indicate the vessels, which are
stained positive for PD-L1. Original mag-
nification 63x. Scale bar represents 50
mm. (D) Double staining (left panel) for
PD-1 (green) and PD-L1 (white) and
triple staining (right panels) for PD-1
(green), PD-L1 (white) and CD3 (red) of a
representative CLL LN tissue section.
Original magnification 63x, zoom factor
of 2 for image on the right. Scale bars
represent 50 mm (left panels) and 25
mm (right panel). (E) Comparative analy-
sis of PD-L1 pixel intensity (arbitrary
units, a.u.) in CD3high vs. CD3low areas
from different LN sections indicates sig-
nificantly higher intensity of expression
in close proximity of PD-1+/CD3+ T lym-
phocytes. For cumulative analysis 10
randomly chosen fields from 3 different
samples were counted. (F) Anti-PD-L1
immunostaining of a representative
reactive LN tissue section. In control
samples the PD-L1 expression is con-
fined to endothelial cells.
Immunohistochemical images were ana-
lyzed using a Leica DMI 3000 B optical
microscope (Leica Microsystesms),
equipped with a DCF 310 FX digital cam-
era and LAS V3.8 software.
Immunofluorescence was analyzed
using a TCS SP5 laser scanning confocal
microscope (Leica Microsystems) with
an oil immersion 63x/1.4 objective lens-
es, images were acquired with the LAS
AF software and processed with Adobe
Photoshop (Adobe Systems). Pixel inten-
sities were calculated with the ImageJ
software.
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with a recombinant soluble form of the PD-L1 ligand to
trigger PD-1+ cells. The production of IFN-γ and IL-4
were selected as indicators of the quality and quantity of
the signals induced and were measured by intracytoplas-
mic staining. Results indicate that T lymphocytes from
CLL patients responded to PD-1 engagement by signifi-
cantly decreasing IL-4 and IFN-γ production in the CD4+
and CD8+ subsets, respectively (Figure 6B). Similar
results were obtained using control T lymphocytes
(Figure 6B). A direct measure of IFN-γ secretion by CLL T
lymphocytes using an ELISpot assay confirmed a signifi-
cant decrease in the presence of soluble PD-L1.
Conversely, treatment with a blocking anti-PD-L1 anti-
body led to a significant increase in IFN-γ secretion by
CLL T lymphocytes. The stimulatory effect was even
more evident when anti-PD-L1 antibody was combined
with an anti-PD-1 reagent (Figure 6C). The same experi-
ments performed using T lymphocytes from age- and
sex-matched donors yielded significant modulation of
IFN-γ production only in the presence of a combination
of blocking anti-PD-1 and anti-PD-L1 antibodies, likely
suggesting that this axis is less active in normal T cells
(Figure 6C). Thus, the engagement of PD-1 and PDL-1
among host T cells and CLL cells within the PC may
skew the immune responses and contribute to a dysreg-
ulated Th2 response.
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Figure 6. IL-4+ and IFN-γ+ pro-
duction by CD4+ and CD8+ T
lymphocytes blocking PD-
1/PD-L1 axis. (A)
Representative dot plots
showing intracytoplasmatic IL-
4 staining in CD4+ (upper
panel) and IFN-γ staining in
CD8+ (lower panel) T lympho-
cytes from CLL patients (left
side) or matched donors (right
side). Cells were tested in
basal conditions or after cul-
ture with mitogenic anti-
CD3/CD28 mAbs. (B)
Cumulative data from 12 CLL
patients (gray box plots) and
12 age- and sex-matched con-
trols (open box plots) are
shown in the box plots in
basal vs. mitogenic condi-
tions. T lymphocytes were oth-
erwise treated with a recombi-
nant soluble form of the PD-L1
ligand. (C) Cumulative data
from ELISpot experiments
showing IFN-γ production by 4
different CLL (gray box plots)
or 4 matched controls (open
box plots) after activation
using anti-CD3 and anti-CD28
antibodies in combination
with soluble PD-L1, anti-PD-1
and anti-PD-L1 antibodies.
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Discussion
Immunoediting is a phenomenon by which cancer cells
alter their phenotype in order to escape attack from the
immune system. Even if this is more effective in the early
stages of tumorigenesis, there is ample evidence to suggest
that during progression tumor cells continue to exploit a
wide variety of subversive processes aimed at maintaining
their own survival.31 At least in solid tumors, one such
process relies on the overexpression of the surface mole-
cule PD-L1, which can engage the co-receptor PD-1 on
surrounding T lymphocytes and inhibit T-cell responses,
consequently permitting cancer progression and
diffusion.32,33 Targeting this receptor-ligand pair using spe-
cific antibody therapy leads to impressive clinical respons-
es in patients with solid tumors of different origins.34,35
On the contrary, data and information on the expression
and function of PD-1 and its ligands in normal and neo-
plastic lymphoid tissues is more limited. In normal human
tonsils, PD-1 appears to be expressed by follicular T-helper
cells localized in the light zone of germinal centers (GCs).38
Germinal center B cells, at least in the mouse, are PD-L1+
and PD-L2+: PD-1/PD-L1 interactions control the full
development of follicular T-helper cells which regulate the
generation of long-lived plasma cells.36 In the neoplastic
context, PD-1 is reported as expressed by tumor infiltrat-
ing, as well as circulating, T lymphocytes in Hodgkin’s and
non-Hodgkin’s lymphomas and in adult T-cell
leukemia.27,37,38 Furthermore, PD-1+ helper T cells were
identified as an independent prognostic risk factor for
decreased overall survival in follicular lymphoma.39
Expression of PD-1 on the neoplastic counterpart was
reported in a limited number of diffuse large B-cell lym-
phomas and in a more significant number of small lym-
phocytic lymphomas. A fraction of circulating CLL cells is
also reported as PD-1+ (see Grzywnowicz et al.17 and Li et
al.18 and confirmed in this work) even if the prognostic and
functional implications remain unknown. 
While comparing PD-1 expression by T lymphocytes in
a cohort of 117 CLL patients to normal donors matched
for age and male/female ratio, we observed a significant
increase in the percentage of positive cells in the CD4+ and
the CD8+ subsets. This finding could be interpreted con-
sidering the altered composition of circulating T lympho-
cytes, marked by decreased naïve T cells and a concomi-
tant increase of more differentiated T subsets. This imbal-
ance is sharpened during disease progression: the number
of effector memory CD4+ and terminally differentiated
CD8+ lymphocytes correlates with clinical and molecular
markers of disease burden and aggressiveness. However,
analysis of PD-1 expression in different T-cell populations,
as divided on the basis of CD45RA and CCR7 expression,
indicated high levels in all subsets, including naïve cells.
This somewhat unexpected result (in the literature, PD-1
is classically associated to a memory phenotype) possibly
reflects an age-related effect. In any case, PD-1 expression
levels were constantly higher in all T-cell subpopulations,
both of CD4 and of CD8 origin, purified from CLL
patients than controls. In the limited cohort of patients
studied, PD-1 expression levels were not significantly
associated to a specific subgroup of patients, at least as
defined by stage of disease, treatment requirements or
expression of molecular or cytogenetic markers of unfa-
vorable prognosis. This negative finding could be
explained considering that cell activation can rapidly mod-
ulate PD-1 expression on T lymphocytes.21 The results of
this work indicate that PD-1 expressed by T lymphocytes
from CLL patients robustly increases when the cells are
activated in an antigen-specific way. An alternative expla-
nation is that the relevant PD-1+ population is the residen-
tial one, only marginally and indirectly represented within
the peripheral pool. In line with this view, immunohisto-
chemical analyses of PD-1 expression within the CLL LN
showed the presence of an intensely positive population
of T lymphocytes. These cells were present at higher den-
sity within the PC and appeared to be in close contact
with CD23+ leukemic elements. Immunofluorescence
studies further indicated that the vast majority of PD-1+ T
cells belong to the CD4 lineage, with no detectable expres-
sion being associated to B cells in this district. On the con-
trary, PD-L1 staining in reactive LN samples was mostly
associated with endothelial cells lining small vessels.40,41 In
the same samples, follicular T-helper cells of CD4 origin
were clearly PD-1+.42 Thus, at least within the LN and with
the limits of these techniques, the paradigm seems to be
that  CD4+/PD-1+ T lymphocytes interact with CD23+/PD-
L1+ leukemic B cells, and this occurs specifically in the CLL
LN. This crosstalk might be relevant in modulating
cytokine production by CD4+ lymphocytes, contributing
to CLL cell activation and proliferation.
PD-L1 expression by a subset of leukemic cells was
maintained in the periphery, with no clear-cut association
with specific markers of the disease, at least in the cohort
analyzed. As in PD-1, PD-L1 might be dynamically
acquired while CLL cells circulate in different environ-
ments, being exquisitely sensitive to the influence of
extracellular signals and conditions. In agreement with
this hypothesis, PD-L1 is inducible in lymphoid cells after
treatment with IFN-γ,43 a cytokine with elevated levels in
the serum of CLL patients.44 Within CLL LN, PD-L1
expression was higher in general and displayed two dis-
tinct patterns. The first was characterized by an intense
and homogenous expression, while the second was char-
acterized by a more focalized expression inside the PC.
These characteristic patterns might indicate that PD-L1+
leukemic lymphocytes are selectively increased in residen-
tial areas, where leukemic proliferation and expansion are
believed to take place. Furthermore, in vitro activation of
CLL cells purified from the peripheral blood was followed
by a sharp increase in the surface expression of PD-L1,
expressed at high density by the majority of cells. PD-L1 is
constitutively expressed at low levels by circulating nor-
mal B lymphocytes, and it is up-regulated significantly less
than in CLL cells. Such different behavior could also be the
result of a different ontogeny of the two populations,
reflecting differentiation specific expression profiles of
nuclear factors driving PD-L1 expression.45
This work also shows that a functional impairment of the
PD-1/PD-L1 pathway is accompanied by an alteration in
the cytokine profile of T lymphocytes. Preliminary in vitro
data obtained by using soluble ligands and blocking anti-
bodies to interfere with the pathway indicates that PD-1
signaling in T lymphocytes leads to further suppression of
IFN-γ secretion, while IL-4 appears less affected. This find-
ing suggests that this receptor ligand pair is involved in
determining the Th2 skewage typically associated with
CLL and is in line with recent data indicating that PD-1
silencing restores physiological mechanisms of the immune
synapse, enabling full activation of T lymphocytes.15
Further studies are needed to fully understand the role
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of PD-1/PD-L1 crosstalk in the complex interactions
undergoing between CLL cells and the host T lympho-
cytes. However, considered together, the data obtained in
this work provide an initial rationale for combining thera-
pies targeting the PD-1/PD-L1 axis with other
immunomodulatory agents that have shown highly prom-
ising activity in this still incurable disease.
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